Epstein-barr Virus
Epstein-barr Virus - Related Videos
06:38
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
0 Views •
Cited by 90 •
2011
We describe a method for generating transformed B cell lines using Epstein-Barr virus. We also illustrate a novel assay that can identify B cells destined to undergo transformation as early as three days after infection.
11:18
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
0 Views •
Cited by 27 •
2012
Here we describe the first good manufacturing practice (GMP)-compliant method of producing virus-specific cytotoxic T lymphocytes (CTL) from umbilical cord blood, a source of predominantly naîve T cells.
09:14
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
0 Views •
Cited by 1 •
2022
This protocol permits the isolation of Epstein-Barr virus particles from the human P3HR1 cell line upon inducing the viral lytic cycle with phorbol 12-myristate 13-acetate. DNA is subsequently extracted from the viral preparation and subjected to real-time PCR to quantify the viral particle concentration.
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
0 Views •
Cited by 1 •
2018
A simple method for obtaining NK and T cell clones from CAEBV patients was developed with high efficiency, a small amount of peripheral blood, and a low-dose of IL-2.
07:35
Rescue and Characterization of Recombinant Virus from a New World Zika Virus Infectious Clone
0 Views •
Cited by 13 •
2017
This protocol describes the recovery of infectious Zika virus from a two-plasmid infectious cDNA clone.
FAQs
EBV uses viral proteins and noncoding RNAs to drive activation of infected B lymphocytes. This altered cellular behavior helps the virus establish persistence rather than being limited to an immediately productive infection. Studying these viral signals allows biologists to connect changes in immune-cell behavior with lifelong infection and with disease processes associated with EBV.
During latency, EBV persists in the host without continuously producing new virus particles. Periodic reactivation changes that state and enables production of new particles, creating an important cycle between persistence and renewed viral activity. This distinction helps researchers examine how EBV remains in the body while still retaining the capacity to spread or contribute to disease-related processes.
Mucosal surfaces represent an important entry context for EBV before the virus reaches its principal immune-cell target, the B lymphocyte. Considering both stages helps researchers study infection as a sequence rather than as an isolated cellular event. This framework is relevant to understanding how exposure, immune-cell alteration, and long-term persistence are biologically connected.
EBV provides a model for examining how an infectious agent can alter immune-cell behavior and remain present over time. Those biological effects are studied alongside EBV-associated diseases, including Hodgkin lymphoma and nasopharyngeal carcinoma. The connection gives biology researchers a way to investigate how viral persistence and cellular alteration relate to disease mechanisms without treating infection and cancer as separate subjects.
Studies can examine several linked outcomes: how EBV enters through mucosal surfaces, how it affects B lymphocytes, how latency is maintained, and how reactivation produces new virus particles. Researchers also investigate immune responses, infectious mononucleosis, and EBV-associated cancers. Together, these outcomes provide a broad view of infection, persistence, host response, and disease.
EBV research contributes to vaccine development by clarifying the biological stages that an intervention might need to address, including entry, immune-cell infection, lifelong persistence, and periodic reactivation. Its connection to infectious mononucleosis and several cancers also gives vaccine research important disease-related goals. These investigations link basic virology with efforts to reduce EBV-associated illness.